These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20215124)

  • 41. Cardiovascular risk and psoriasis: a role in clinical cardiology?
    Imbalzano E; Casale M; D'Angelo M; Mandraffino G; Giugno V; Di Bella G; Carerj S; Dattilo G
    Angiology; 2015 Feb; 66(2):101-3. PubMed ID: 24671131
    [No Abstract]   [Full Text] [Related]  

  • 42. Where the immune response meets the vessel wall.
    Bisoendial RJ; Stroes ES; Tak PP
    Neth J Med; 2009 Sep; 67(8):328-33. PubMed ID: 19767659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease: the Louis F. Bishop Lecture.
    Gotto AM
    J Am Coll Cardiol; 2005 Oct; 46(7):1219-24. PubMed ID: 16198834
    [No Abstract]   [Full Text] [Related]  

  • 44. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study.
    Gisondi P; Tessari G; Conti A; Piaserico S; Schianchi S; Peserico A; Giannetti A; Girolomoni G
    Br J Dermatol; 2007 Jul; 157(1):68-73. PubMed ID: 17553036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Obesity, inflammation, and cardiovascular risk.
    Mathieu P; Lemieux I; Després JP
    Clin Pharmacol Ther; 2010 Apr; 87(4):407-16. PubMed ID: 20200516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Frontiers in research series: Physiological and pathological functions of high-density lipoprotein. Introduction.
    Sviridov D
    Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):700-2. PubMed ID: 20374253
    [No Abstract]   [Full Text] [Related]  

  • 47. The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?
    Blankenberg S; Yusuf S
    Circulation; 2006 Oct; 114(15):1557-60. PubMed ID: 17030701
    [No Abstract]   [Full Text] [Related]  

  • 48. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is serum amyloid A protein a better indicator of inflammation in severe psoriasis?
    Dogan S; Atakan N
    Br J Dermatol; 2010 Oct; 163(4):895-6. PubMed ID: 20553266
    [No Abstract]   [Full Text] [Related]  

  • 50. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community.
    Menter A; Griffiths CE; Tebbey PW; Horn EJ; Sterry W;
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1371-7. PubMed ID: 20384692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies.
    Gu WJ; Weng CL; Zhao YT; Liu QH; Yin RX
    Int J Cardiol; 2013 Oct; 168(5):4992-6. PubMed ID: 23931969
    [No Abstract]   [Full Text] [Related]  

  • 52. Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals.
    Kaur-Knudsen D; Bojesen SE; Nordestgaard BG
    Pharmacogenomics J; 2009 Oct; 9(5):327-32. PubMed ID: 19652664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.
    Driessen RJ; Boezeman JB; Van De Kerkhof PC; De Jong EM
    J Dermatolog Treat; 2009; 20(1):42-7. PubMed ID: 18649164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endothelial dysfunction in obesity: etiological role in atherosclerosis.
    Meyers MR; Gokce N
    Curr Opin Endocrinol Diabetes Obes; 2007 Oct; 14(5):365-9. PubMed ID: 17940464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic inflammation as a driver of vascular calcification: a proof of concept.
    Shantsila E; Lip GY
    J Intern Med; 2009 Nov; 266(5):453-6. PubMed ID: 19817967
    [No Abstract]   [Full Text] [Related]  

  • 56. Xanthelasma and cardiovascular risk.
    Crook M
    Int J Clin Pract; 2008 Feb; 62(2):178-9. PubMed ID: 18199275
    [No Abstract]   [Full Text] [Related]  

  • 57. Psoriasis as the marker of underlying systemic disease.
    Kourosh AS; Miner A; Menter A
    Skin Therapy Lett; 2008 Feb; 13(1):1-5. PubMed ID: 18357363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene.
    Goulding JM; Price CL; Defty CL; Hulangamuwa CS; Bader E; Ahmed I
    Br J Dermatol; 2011 Jan; 164(1):103-9. PubMed ID: 20874856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.
    Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C
    Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?
    Doumas M; Katsiki N; Papademetriou V
    Angiology; 2018 Jan; 69(1):5-9. PubMed ID: 28401789
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.